Business Wire

PUMA

Share
PUMA and Modibodi® Present Range of Period Underwear for Women

Sports company PUMA and global leak-proof apparel company Modibodi® have teamed up to launch a range of leak-free period underwear and activewear, created to help women stay comfortable and active during their period whilst making a positive environmental impact.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220301005090/en/

PUMA together with Modibodi believes that everybody who wants to participate in exercise or sport should be given the opportunity to stay active and play, fueling the motivation behind PUMA x Modibodi’s exclusive global partnership under the “She Moves Us” platform.

“Even in the 21st century, periods and leaks still prevent women from participating in sports. Studies have revealed that girls’ participation in sport drops from 69% (ages 11-12) to 45% (ages 13-15)*. Additionally, the single-use plastic from disposable products can continue to pollute the environment for hundreds of years,” said Erin Longin, Global Director Run/Train at PUMA. “As a global brand, we felt it important to do our part to address this issue. The PUMA x Modibodi collaboration allows women to stay active, without having to worry about leaks, while reducing their monthly waste from period products.”

Disposable products pollute the environment and are more expensive long term than their reusable, sustainable counterparts. The PUMA x Modibodi collection is designed to be reused and replaces the need for disposable pads, liners and tampons, whilst ensuring women can stay extremely comfortable, odor free and protected from all leaks (not just periods). Modibodi’s proprietary Modifier Technology™ achieves this through its soft top layer, made of merino wool, which wicks moisture and sweat, a quick-drying absorbent microfibre middle layer, that locks away fluid and odor, and an additional waterproof protection in the bottom layer.

“No woman should have to sit on the sidelines of life because they have their period or bladder leaks,” said Kristy Chong, CEO and Founder, Modibodi. “We are thrilled to launch this collection with PUMA and together normalize menstruation and tackle the stigma that women can't be active on their periods or when experiencing any of life’s leaks.”

As part of the launch, PUMA and Modibodi will work with PUMA’s She Moves Us charity partner, Women Win , to donate a bundle pack of five briefs to 500 girls and women in need. This five-pack bundle covers a person for their monthly cycle and will last for up to four years to allow the person to confidently participate in sport and life without life’s leaks getting in the way.

The first PUMA x Modibodi active underwear collection will be available in May 2022 in selected stores and online at puma.com and modibodi.com.

*Observatory for Sport in Scotland (OSS) https://oss.scot/sport-participation-in-scotland-trends-and-future-prospects/

PUMA

PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For more than 70 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 14,000 people worldwide, and is headquartered in Herzogenaurach/Germany.

MODIBODI

Founded in 2013, Modibodi® is Australia’s original leak-proof apparel brand, designing underwear, swimwear, active wear, maternity wear and reusable nappies to replace disposable hygiene products and offer a sustainable solution to manage periods, incontinence, discharge, breast milk leaks, sweat and more. Modibodi is warm, authentic and human. We help people with all kinds of leaky bodies get on with their lives. We’re plain speaking and taboo breaking. We’re comfortable in our own skin and not embarrassed to talk about leaky bodies – because they’re part of life. We offer a range of products and sizes across our three brands: Modibodi®, Modibodi RED for tweens and teens, and Modibodi Men to manage incontinence, sweat and chafing. Our Modibodi leak-proof products have been scientifically tested and proven to absorb fluid, resist odour, and keep you dry, thanks to the brand’s patented technology which keeps you feeling comfortable and confident and reduces the impact on the environment. Modibodi is committed to sustainability and social impact, helping end period poverty and normalising conversations about periods and leaks through education and supporting people in need globally. To date, Modibodi has sold millions of garments worldwide, saving billions of single-use disposable hygiene products such as pads, liners and tampons from ending up in landfill.

Changing the world should be as easy as changing your underwear. Waste-free, leak-free, worry-free protection.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye